Two-year Safety Study of Dorzolamide as Monotherapy and With Timolol and Pilocarpine. Dorzolamide Safety Study Group

摘要: Purpose To evaluate the safety of open-label 2.0% dorzolamide as monotherapy and when used with timolol and/or pilocarpine for long 2 years. Methods The was evaluated in patients open-angle glaucoma or ocular hypertension over a 2-year period. incidence most common drug-related adverse experiences first year compared that second using McNemar's test. hypotensive effect adjunctive therapy assessed percent change intraocular pressure (IOP) from baseline. Results Of 304 enrolled, 164 (53.9%) continued to receive years 140 (46.1%) required add-on therapy. Add-on initiated by month 6 112 these (80%). patients, 202 (66.4%) completed who received monotherapy, events occurred more frequently during (29.7%) than (13.8%), included conjunctivitis, burning/stinging eye, follicular eyelid edema. After therapy, mean decrease peak IOP 22.8% receiving 31.2% 36.0% Conclusion Dorzolamide generally well tolerated up mono-therapy pilocarpine. Drug-related were less frequent year. Most did so within months initiating